Drugs for Hidradenitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 88)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Triamcinolone |
Approved, Vet_approved |
Phase 4 |
|
124-94-7 |
31307 |
Synonyms:
11b,16a,17a,21-Tetrahydroxy-9a-fluoro-1,4-pregnadiene-3,20-dione
11beta,16alpha,17alpha,21-Tetrahydroxy-9alpha-fluoro-1,4-pregnadiene-3,20-dione
11Β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
9a-Fluoro-11b,16a,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9a-Fluoro-11b,16a,17a,21-tetrahydroxypregna-1,4-diene-3,20-dione
9a-Fluoro-16a-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9-Fluoro-11b,16a,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-16α-hydroxyprednisolone
Adcortyl
Aristocort
ARISTOCORT A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
Celeste
Cinolone
Cinolone-T
DELPHICORT
Fluoxiprednisolone
fluoxiprednisolone|Kenalog®|Nasacort®
Fluoxyprednisolone
Flutex
Fougera
Kenacort
Kenacort-A
Kenacort-Ag
KENALOG
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
Ledercort
|
NASACORT
Nasacort Aq
Nasacort Hfa
NSC-13397
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Rodinolone
Sk-Triamcinolone
TIAMCINOLONUM
Tiamcinolonum [INN-Latin]
Triacet
Triacort
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
TRIAMCINOLONE
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Triam-Tablinen
Triatex
Tricortale
Triderm
Trilone
Tri-Nasal
Tristoject
Trymex
Vetalog
Volon
Volon A
|
|
2 |
|
Anesthetics |
|
Phase 4 |
|
|
|
3 |
|
Triamcinolone hexacetonide |
|
Phase 4 |
|
|
|
Synonyms:
ARISTOSPAN
CL-34433
LEDERSPAN
|
TATBA
TRIAMCINOLONE HEXACETONIDE
|
|
4 |
|
Triamcinolone diacetate |
|
Phase 4 |
|
|
|
Synonyms:
ARISTOCORT
KENACORT
ORION
POLCORTOLON
|
TEDAROL
TRIAMCINOLONE 16,21-DIACETATE
TRIAMCINOLONE DIACETATE
|
|
5 |
|
Triamcinolone Acetonide |
|
Phase 4 |
|
|
6436 |
Synonyms:
ADCORTYL
ADCORTYL IN ORABASE
ALLERNAZE
ARISTOCORT
ARISTOCORT A
ARISTOGEL
AUDICORT
AUREOCORT
AZMACORT
FLUTEX
GPPE EAR DPS CAP
GPPE EAR OINT
KENACORT
KENACOURT
KENALOG
KENALOG IN ORABASE
KENALOG-10
KENALOG-40
KENALOG-80
KENALOG-H
NASACORT
NASACORT ALLERGY 24 HOUR
NASACORT AQ
|
NASACORT HFA
NSC-21916
NYSTADERMAL
ORACORT
ORALONE
PEVARYL T.C.
REMIDERM
REMOTIC
SILDERM
TRIACET
TRIACORT
TRI-ADCORTYL
TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE IN ABSORBASE
TRIATEX
TRIDERM
TRIESENCE
TRI-NASAL
TRIVARIS
TRYMEX
VETALOG
ZILRETTA
Zilretta®
|
|
6 |
|
glucocorticoids |
|
Phase 4 |
|
|
|
7 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
8 |
|
Immunosuppressive Agents |
|
Phase 4 |
|
|
|
9 |
|
Metformin |
Approved |
Phase 3 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
10 |
|
Doxycycline |
Approved, Investigational, Vet_approved |
Phase 3 |
|
564-25-0 |
54671203 |
Synonyms:
(4S,4AR,5S,5ar,6R,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
5-Hydroxy-a-6-deoxytetracycline
5-Hydroxy-alpha-6-deoxytetracycline
5-Hydroxy-α-6-deoxytetracycline
6a-Deoxy-5-oxytetracycline
6-alpha-deoxy-5-oxytetracycline
6alpha-Deoxy-5-oxytetracycline
6Α-deoxy-5-oxytetracycline
Anhydrous doxycycline
BMY-28689|Monodox®|Vibramycin®
Doxcycline anhydrous
Doxiciclina
DOXY
Doxychel
Doxycyclin
Doxycycline
|
Doxycycline (anhydrous)
DOXYCYCLINE ANHYDROUS
DOXYCYCLINE HCL
Doxycycline hyclate
Doxycycline hydrate
Doxycycline hydric acid
Doxycycline monohydrate
Doxycycline monohydric acid
Doxycyclinum
Doxytetracycline
GS-3065
Jenacyclin
Monodox
Oracea
Supracyclin
Vibramycin
|
|
11 |
|
Hypoglycemic Agents |
|
Phase 3 |
|
|
|
12 |
|
Anti-Bacterial Agents |
|
Phase 3 |
|
|
|
13 |
|
Antibiotics, Antitubercular |
|
Phase 3 |
|
|
|
14 |
|
Hydroxychloroquine |
Approved |
Phase 1, Phase 2 |
|
118-42-3 |
3652 |
Synonyms:
(+-)-Hydroxychloroquine
(±)-HYDROXYCHLOROQUINE
2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
7-Chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(N-ethyl-N-b-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-[4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino]quinoline
7-Chloro-4-[4-(N-ethyl-N-b-hydroxyethylamino)-1-methylbutylamino]quinoline
7-Chloro-4-[4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline
7-Chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
Axemal
DOLQUINE
Dolquine®|Plaquenil®
Ercoquin
Gen-Hydroxychloroquine 200mg Tablets
HCQ
Hidroxicloroquina
|
Hidroxicloroquina [inn-spanish]
Hydroxychlorochin
Hydroxychloroguine
HYDROXYCHLOROQUINE
Hydroxychloroquine sulfate
Hydroxychloroquine sulfate (1:1) salt
Hydroxychloroquinum
Hydroxychloroquinum [inn-latin]
Idrossiclorochina [dcit]
NSC4375
Oxichlorochine
Oxichlorochinum
Oxichloroquine
Oxychlorochin
Oxychloroquine
Plaquenil
Polirreumin
Quensyl
|
|
15 |
|
Apremilast |
Approved, Investigational |
Phase 2 |
|
608141-41-9 |
10151715 11561674 |
Synonyms:
APREMILAST
APRÉMILAST
APREMILASTUM
CC 10004
CC10004
|
CC-10004
CC-10004|Otezla®
N-{2-[(1S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYLSULFONYL)ETHYL]-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YL}ACETAMIDE
OTEZLA
|
|
16 |
|
Infliximab |
Approved |
Phase 2 |
|
170277-31-3 |
|
Synonyms:
ABP 710
BOW015
CA2
CA2 ????
IG GAMMA-1 CHAIN C REGION
INFLECTRA
INFLIXIMAB
Infliximab (genetical recombination)
|
Infliximab-abda
Infliximab-axxq
Infliximab-dyyb
Infliximab-qbtx
NI-071
REMICADE
REMSIMA
TA-650
|
|
17 |
|
Ustekinumab |
Approved, Investigational |
Phase 2 |
|
815610-63-0 |
|
Synonyms:
CNTO-1275
STELARA
STELERA
|
|
|
18 |
|
Etanercept |
Approved, Investigational |
Phase 2 |
|
185243-69-0 |
|
Synonyms:
BENEPALI
CD120B
ENBREL
Enbrel Sureclick
Etanercept
etanercept-szzs
etanercept-ykro
FC
GP2015
GP-2015
GP2015C
HD203
L04AB01
|
LBEC0101
P75
P80 TNF-ALPHA RECEPTOR
Recombinant human TNF
RHU TNFR
rhu TNFR:Fc
rhu-TNFR:Fc
TNF-R2
TNFR-Immunoadhesin
TUMOR NECROSIS FACTOR RECEPTOR 2
TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 1B PRECURSOR
TUMOR NECROSIS FACTOR RECEPTOR TYPE II
|
|
19 |
|
Upadacitinib |
Approved, Investigational |
Phase 2 |
|
1310726-60-3 |
76829165 58557659 |
Synonyms:
3-Ethyl-4-{1,5,7,10-tetraazatricyclo[7.3.0.0,]dodeca-2(6),3,7,9,11-pentaen-12-yl}-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboximidate
ABT-494
|
ABT-494|Rinvoq®
UPADACITINIB
|
|
20 |
|
Tofacitinib |
Approved, Investigational |
Phase 2 |
|
477600-75-2 |
9926791 |
Synonyms:
550
CP- 690 550
CP 690550
CP-690
CP690,550
CP-690,550
CP-690,550 FREE BASE
CP-690,550|CP-690550|tasocitinib|Xeljanz®
|
CP690550
CP-690550
CP-690-550
CP-690550 FREE BASE
TASOCITINIB
TOFACITINIB
Tofacitinibum
XELJANZ
|
|
21 |
|
Benzocaine |
Approved, Investigational |
Phase 2 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
22 |
|
Tannic acid |
Approved |
Phase 2 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
23 |
|
Methylene blue |
Approved, Investigational |
Phase 2 |
|
61-73-4 |
6099 |
Synonyms:
3,7-BIS(DIMETHYLAMINO)PHENAZATHIONIUM CHLORIDE
aniline violet
Azul de metileno
BASIC BLUE 9
C.I. 52015
C.I. BASIC BLUE 9
Chlorure de méthylthioninium
CI 52015
CI-52015
Cloruro de metiltioninio
EHRLICH'S REAGENT III
LOWACRYL BLUE 9
METHYLENE BLUE
METHYLENE BLUE ANHYDROUS
METHYLENE BLUE TRIHYDRATE
|
METHYLENIUM CERULEUM
METHYLTHIONINE CHLORIDE
METHYLTHIONINE HCL
Methylthioninii chloridum
METHYLTHIONINIUM CHLORIDE
methylthioninium chloride Proveblue
NSC-215213
NSC-617593
PROVAYBLUE
SOLVENT BLUE 8
SWISS BLUE
tetrametylthionine chloride
TRX0014
UROLENE BLUE
VIB100
|
|
24 |
|
Gentian violet cation |
Approved |
Phase 2 |
|
14426-25-6, 7438-46-2 |
3468 11057 |
Synonyms:
ANILINE VIOLET
BASIC VIOLET 3
BASIC VIOLET BN
Crystal violet
Crystal violet carbocation
Crystal violet ion(1)
Crystal violet(1+)
GENAPAX
GENTIAN VIOLET
Gentian violet carbocation
Gentian violet cation
Gentian violet(1+)
GENTIAVERM
GNF-PF-880
GV 11
|
GVS
HEXAMETHYL PARAROSANILINE CHLORIDE
HEXAMETHYL VIOLET
METHYL VIOLET
METHYL VIOLET 10B
Methylrosaniline
METHYLROSANILINE CHLORIDE
METHYLROSANILINE CL
Methylrosanilinium
METHYLROSANILINIUM CHLORIDE
METHYLROSANILINIUM CL
NSC-3090
PYOKTANIN
VIOCID
|
|
25 |
|
Glycerin |
Approved, Investigational |
Phase 2 |
|
56-81-5 |
753 |
Synonyms:
(2,5-Dihydroxyphenyl)-acetate
(2,5-Dihydroxyphenyl)-acetic acid
(2E)-2-Butenedioate
(2E)-2-Butenedioic acid
(2E)-But-2-enedioate
(2E)-But-2-enedioic acid
(e)-2-Butenedioate
(e)-2-Butenedioic acid
1,2,3-Propanetriol
1,2,3-Trihydroxypropane
2-(3,6-DIHYDROXYPHENYL)acetate
2-(3,6-DIHYDROXYPHENYL)acetIC ACID
2-(e)-Butenedioate
2-(e)-Butenedioic acid
2,5-Dihydroxy-alpha-toluate
2,5-Dihydroxy-alpha-toluic acid
2,5-Dihydroxy-a-toluate
2,5-Dihydroxy-a-toluic acid
2,5-Dihydroxy-benzeneacetate
2,5-Dihydroxy-benzeneacetic acid
2,5-Dihydroxyphenylacetate
2,5-Dihydroxyphenylacetic acid
Acid, homogentisic
Alcapton
Allomaleate
Allomaleic acid
alpha-delta-Glucopyranuronic acid
alpha-delta-Glucuronic acid
alpha-D-Glucopyranuronic acid
alpha-D-Glucuronic acid
Ammonium fumarate
Boletate
Boletic acid
Bulbold
Concentrated glycerin
Cristal
D-(+)-Glucuronate
D-(+)-Glucuronic acid
delta-(+)-Glucuronate
delta-(+)-Glucuronic acid
delta-Glucuronate
D-Glucuronate
e 422
e297
Emery 916
FC 33
Fumarate
Fumarsaeure
Furamag
GCU
GlcAa
GlcAalpha
|
Glucosiduronate
Glucosiduronic acid
Glucuronate
Glucuronic acid
Glyceol opthalgan
Glycerin
Glycerin, anhydrous
Glycerin, concentrated
Glycerin,anhydrous
Glycerine
glycérine
Glycerinum
Glyceritol
Glycerol
glycérol
Glycerolum
Glycyl alcohol
Glyrol
Glysanin
Glyzerin
Gro
Homogentisate
Homogentisate acid
Homogentisinate
Homogentisinic acid
IFP
Incorporation factor
Lichenate
Lichenic acid
Mackstat H 66
Mafusol
Magnesium fumarate
Melanic acid
Monoctanoin component D
Oelsuess
Ölsüß
Osmoglyn
Pricerine 9091
Propanetriol
RG-S
Sodium fumarate
trans-1,2-Ethylenedicarboxylate
trans-1,2-Ethylenedicarboxylic acid
trans-2-Butenedioate
trans-2-Butenedioic acid
trans-But-2-enedioate
trans-But-2-enedioic acid
trans-Butenedioate
trans-Butenedioic acid
Trihydroxypropane
Tryhydroxypropane
|
|
26 |
|
Estradiol |
Approved, Investigational, Vet_approved |
Phase 2 |
|
50-28-2 |
5757 |
Synonyms:
(+)-3,17B-ESTRADIOL
(17b)-Estra-1,3,5(10)-triene-3,17-diol
(17BETA)-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
(17Î’)-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
(1S,10R,11S,14S,15S)-15-METHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADECA-2,4,6-TRIENE-5,14-DIOL
(8R,9S,13S,14S,17S)-13-METHYL-6,7,8,9,11,12,14,15,16,17-DECAHYDROCYCLOPENTA[A]PHENANTHRENE-3,17-DIOL
[<sup>3</sup>H]-estradiol|[<sup>3</sup>H]-estrogen|[<sup>3</sup>H]E2|[<sup>3</sup>H]estradiol
13B-METHYL-1,3,5(10)-GONATRIENE-3,17B-OL
17 beta Estradiol
17 beta Oestradiol
17 beta-Estradiol
17 beta-Oestradiol
17b Oestradiol
17b-Estra-1,3,5(10)-triene-3,17-diol
17B-ESTRADIOL
17BETA OESTRADIOL
17BETA-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
17BETA-ESTRADIOL
17BETA-OESTRADIOL
17B-OESTRADIOL
17Î’ oestradiol
17Î’-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
17β-estradiol
17Î’-OESTRADIOL
3,17B-DIHYDROXYESTRA-1,3,5(10)-TRIENE
3,17B-ESTRADIOL
3,17-EPIDIHYDROXYESTRATRIENE
ADGYN ESTRO
AERODIOL
AGOFOLLIN
ALFATRADIOL
ALORA
ALTRAD
AMNESTROGEN
AQUADIOL
AQUAGEN
BARDIOL
BEDOL
B-ESTRADIOL
BETA-ESTRADIOL
CIS-ESTRADIOL
CLIMADERM
CLIMARA
CLIMARA PRO
COMPUDOSE
CORPAGEN
Delestrogen
DELTA-ESTRADIOL
DELTA-OESTRADIOL
DEPO-ESTRADIOL
DERMESTRIL
DERMESTRIL 100
DERMESTRIL 25
DERMESTRIL 50
DERMESTRIL SEPTEM 25
DERMESTRIL SEPTEM 50
DERMESTRIL SEPTEM 75
DESTRADIOL
D-ESTRADIOL
DIHYDROFOLLICULAR HORMONE
DIHYDROFOLLICULIN
DIHYDROMENFORMON
DIHYDROTHEELIN
DIHYDRO-THEELIN
DIHYDROXYESTRIN
DIMENFORMON
DIOGYN
DIOGYNETS
DIVIGEL
D-OESTRADIOL
E2
E2|estrogen|oestrodiol|oestrogen
E-CYPIONATE
ELESTRIM
ELESTRIN
ELLESTE SOLO
ELLESTE SOLO MX 40
ELLESTE SOLO MX 80
ENCORE
EPIESTRIOL 50
ESCLIM
ESTRA-1,3,5(10)-TRIENE-3,17B-DIOL
ESTRACE
ESTRADERM
ESTRADERM MX 100
ESTRADERM MX 25
ESTRADERM MX 50
ESTRADERM MX 75
ESTRADERM TTS
ESTRADERM TTS 100
ESTRADERM TTS 25
ESTRADERM TTS 50
ESTRADIOL
Estradiol 17 alpha
Estradiol 17 beta
Estradiol 17beta
Estradiol anhydrous
ESTRADIOL HEMIHYDRATE
Estradiol hemihydrate, (17 alpha)-isomer
Estradiol monohydrate
Estradiol orion brand
Estradiol valerate
Estradiol valeriante
|
Estradiol, (-)-isomer
Estradiol, (+-)-isomer
Estradiol, (16 alpha,17 alpha)-isomer
Estradiol, (16 alpha,17 beta)-isomer
Estradiol, (17-alpha)-isomer
Estradiol, (8 alpha,17 beta)-(+-)-isomer
Estradiol, (8 alpha,17 beta)-isomer
Estradiol, (9 beta,17 alpha)-isomer
Estradiol, (9 beta,17 beta)-isomer
Estradiol, monosodium salt
Estradiol, sodium salt
Estradiol-17 alpha
Estradiol-17 beta
Estradiol-17b
ESTRADIOL-17BETA
ESTRADIOL-17-BETA
Estradiol-17β
ESTRADIOLUM
ESTRADOT
ESTRALDINE
ESTRASORB
ESTRING
ESTRING VAGINAL RING
ESTROCLIM
ESTROCLIM 50
ESTROGEL
ESTROGEL HBF
ESTROGEN
ESTROVITE
EVAMIST
EVOREL
EVOREL 100
EVOREL 25
EVOREL 50
EVOREL 75
FEMATRIX 40
FEMATRIX 80
FEMESTRAL
FEMOGEN
FEMPATCH
FEMSEVEN 100
FEMSEVEN 50
FEMSEVEN 75
FOLLICYCLIN
GELESTRA
GINOSEDOL
GVNODIOL
GYNERGON
GYNODIOL
GYNOESTRYL
GYNOGEN
IMVEXXY
INNOFEM
LAMDIOL
MACRODIOL
MENOREST
MENOREST 37.5
MENOREST 50
MENOREST 75
MENORING 50
MENOSTAR
MINIVELLE
NORDICOL
Novartis pharmaceuticals brand OF estradiol
NSC-20293
NSC-9895
OESCLIM
OESTERGON
OESTRA-1,3,5(10)-TRIENE-3,17B-DIOL
OESTRADIOL
OESTRODIOL
OESTROGEL
OESTROGEN
OESTROGLANDOL
Orion brand OF estradiol
OVAHORMON
OVASTEROL
OVASTEVOL
OVOCYCLIN
OVOCYLIN
PERLATANOL
PRIMOFOL
PROFOLIOL
PROFOLIOL B
PROGYNON
Progynon depot
PROGYNON DH
Progynon-depot
Progynova
PROGYNOVA TS
SANDRENA
SANDRENA 1
SYNDIOL
SYSTEN
VAGIFEM
VAGIFEM 18
VAGIFEM 8
VIVELLE
VIVELLE-DOT
WC3011
WC-3011
ZUMENON
Î’-estradiol
|
|
27 |
|
Ethinylestradiol |
Approved |
Phase 2 |
|
57-63-6 |
5991 |
Synonyms:
(1S,10R,11S,14R,15S)-14-ETHYNYL-15-METHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADECA-2,4,6-TRIENE-5,14-DIOL
17 ALPHA-ETHINYLESTRADIOL
17 ALPHA-ETHYNYLESTRADIOL
17 ALPHA-ETHYNYLOESTRADIOL
17α-ethynylestradiol|ethinyl estradiol
17a-Ethinyl estradiol
17a-Ethinyl-17b-estradiol
17a-Ethinylestradiol
17a-Ethynyl-17b-oestradiol
17a-Ethynylestradiol-L7b
17a-Ethynyloestradiol
17a-Ethynyloestradiol-17b
17alpha-Ethinyl estradiol
17-Ethinyl-3,17-estradiol
17-Ethinyl-3,17-oestradiol
17-Ethinylestradiol
17-Ethynylestradiol
17-Ethynylestradiol ram
17-Ethynyloestradiol
17Α-ethinyl estradiol
17Α-ETHYNYLESTRADIOL
Alora
Amenoron
Anovlar
Chee-O-gen
Chee-O-genf
Diognat-e
Diogyn e
Diogyn-e
Dyloform
Effik brand OF ethinyl estradiol
ENOVID
ENOVID-E
Ertonyl
Esclim
Esteed
Estigyn
Estinyl
Eston-e
Estoral
Estoral {[orion]}
Estorals
Estradiol, ethinyl
Estradiol, ethynyl
Estring
Estrogen
Ethidol
Ethinoral
Ethinyl estradiol
Ethinyl estradiol hemihydrate
Ethinyl estradiol, (8 alpha)-isomer
Ethinyl estradiol, (8 alpha,17 alpha)-isomer
Ethinyl estradiol, (8 alpha,9 beta,13 alpha,14 beta)-isomer
Ethinyl estradiol, (9 beta,17 alpha)-isomer
Ethinyl oestradiol effik
Ethinylestradiol
Ethinylestradiol jenapharm
ETHINYLESTRADIOLUM
Ethinylestriol
Ethinyloestradiol
|
Ethinyl-oestradiol effik
ETHINYL-OESTRANOL
Ethynyl estradiol
Ethynylestradiol
ETHYNYLOESTRADIOL
Eticyclin
Eticyclol
Eticylol
Etinestrol
Etinestryl
ETINILESTRADIOL
Etinoestryl
Etistradiol
Etivex
Feminone
Fempatch
Follicoral
Ginestrene
Gynodiol
Gynolett
Hemihydrate, ethinyl estradiol
Inestra
Innofem
Jenapharm brand OF ethinyl estradiol
Jenapharm, ethinylestradiol
Kolpolyn
Linoral
Lynoral
Menolyn
Menostar
Microfollin
Microfollin forte
Neo-estrone
Nogest-S
NORINYL
Novestrol
NSC-10973
Oradiol
Orestralyn
Orestrayln
Organon brand OF ethinyl estradiol
Ovex
OVULEN
OVULEN-21
OVULEN-28
Palonyl
Perovex
Primogyn
Primogyn C
Primogyn m
Progynon C
Progynon m
Schering brand OF ethinyl estradiol
Schering-plough brand OF ethinyl estradiol
Spanestrin
Thiuram e
Thiuranide
Vagifem
Ylestrol
|
|
28 |
|
Polyestradiol phosphate |
Approved |
Phase 2 |
|
28014-46-2 |
|
Synonyms:
(17-beta)-Estra-1,3,5(10)-triene-3,17-diol polymer with phosphoric acid
ESTRADIOL PHOSPHATE
Estradiol phosphate polymer
ESTRADURIN
Fosfato de poliestradiol
LEO-114
Oestradiol phosphate polymer
|
Phosphate de polyestradiol
Poly(estradiol phosphate)
POLYEST PHOS
POLYESTRADIOL PHOS PHOSPHATE
POLYESTRADIOL PHOSPHATE
Polyestradioli phosphas
|
|
29 |
|
Drospirenone |
Approved |
Phase 2 |
|
67392-87-4 |
68873 |
Synonyms:
1,2-Dihydrospirorenone
1,2-Dihydro-spirorenone
15b,16b-dimethylene-3-oxo-17a-pregn-4-ene-21,17-carbolactone
15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone
6b,7Beta
6beta,7Beta
6beta,7beta,15beta,16beta-Dimethylen-3-oxo-17alpha-pregn-4-en-21,17-carbolacton
6BETA,7BETA;15BETA,16BETA-DIMETHYLENE-3-OXO-17ALPHA-PREGN-4-ENE-21,17-CARBOLACTONE
6Î’,7beta
6β,7β
6Β,7β,15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17 carbolactone
ANGELIQ
|
Dehydrospirorenone
Dihydrospirorenone
dihydrospirorenone|Slynd®|Yasmin®|ZK30595
Drospirenona
DROSPIRENONE
Drospirénone
Drospirenonum
DRSP
Slynd
YASMIN
ZK30595
ZK-30595
|
|
30 |
|
Glutamic acid |
Approved, Nutraceutical |
Phase 2 |
|
56-86-0 |
33032 |
Synonyms:
(+)-Estrone
(1S)-2-[(3-O-b-D-Glucopyranosyl-b-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoate
(1S)-2-[(3-O-b-D-Glucopyranosyl-b-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoic acid
(1S)-2-[(3-O-beta-D-Glucopyranosyl-beta-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoic acid
(1S)-2-[(3-O-Β-D-glucopyranosyl-β-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoate
(1S)-2-[(3-O-Β-D-glucopyranosyl-β-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoic acid
(2R)-2,3-Dihydroxypropanoic acid
(2S)-2-Aminopentanedioate
(2S)-2-Aminopentanedioic acid
(3R,4S,5R)-5-[(1R)-1-Carboxy-2,2-difluoro-1-(phosphonooxy)ethoxy]-4-hydroxy-3-(phosphonooxy)cyclohex-1-ene-1-carboxylate
(R)-2,3-Dihydroxypropanoic acid
(R)-Glycerate
(R)-Glyceric acid
(S)-(+)-Glutamate
(S)-(+)-Glutamic acid
(S)-2-Aminopentanedioate
(S)-2-Aminopentanedioic acid
(S)-Glutamate
(S)-Glutamic acid
1,3,5(10)-Estratrien-3-ol-17-one
1-Amino-2-hydroxyethane
1-Aminopropane-1,3-dicarboxylate
1-Amino-propane-1,3-dicarboxylate
1-Aminopropane-1,3-dicarboxylic acid
1-Amino-propane-1,3-dicarboxylic acid
2 Acetamido 2 deoxy D glucose
2 Acetamido 2 deoxyglucose
2 Aminoethanol
2-Acetamido-2-deoxy-D-glucose
2-Acetamido-2-deoxyglucose
2-Amino-1-ethanol
2-Aminoethan-1-ol
2-Aminoethanol
2-Amino-ethanol
2-Aminoethyl alcohol
2-Aminoglutarate
2-Aminoglutaric acid
2-Aminopentanedioate
2-Aminopentanedioic acid
2-Ethanolamine
2-Hydroxyethanamine
2-Hydroxyethylamine
3a,7a,12a-Trihydroxy-5b-cholan-24-oylglycine
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oylglycine
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid-24-glycine
3alpha,7alpha,12alpha-Trihydroxy-N-(carboxymethyl)-5beta-cholan-24-amide
3-Hydroxy-1,3,5(10)-estratrien-17-one
3-Hydroxy-17-keto-estra-1,3,5-triene
3-Hydroxyestra-1,3,5(10)-trien-17-one
3-Hydroxyestra-1,3,5(10)-triene-17-one
3-Hydroxyoestra-1,3,5(10)-trien-17-one
3Α,7α,12α-trihydroxy-5β-cholan-24-oylglycine
3Α,7α,12α-trihydroxy-5β-cholanic acid-24-glycine
3Α,7α,12α-trihydroxy-N-(carboxymethyl)-5β-cholan-24-amide
a,b-Hydroxypropionate
a,b-Hydroxypropionic acid
a-Aminoglutarate
a-Aminoglutaric acid
Acetylglucosamine
Acide glutamique
Acido glutamico
ácido glutámico
Acidum glutamicum
Aciglut
Aethanolamin
a-Glutamate
a-Glutamic acid
alpha,beta-Hydroxypropionate
alpha,beta-Hydroxypropionic acid
alpha-Aminoglutarate
alpha-Aminoglutaric acid
alpha-Glutamate
alpha-Glutamic acid
Aluminum L glutamate
Aluminum L-glutamate
Aminoethanol
Aminoglutarate
Aminoglutaric acid
b-Aminoethanol
b-Aminoethyl alcohol
beta-Aminoethanol
beta-Aminoethyl alcohol
beta-Ethanolamine
beta-Hydroxyethylamine
b-Ethanolamine
b-Hydroxyethylamine
Cholylglycine
Colamine
D Glutamate
D1,3,5(10)-Estratrien-3-ol-17-one
D-2,3-Dihydroxypropanoic acid
D-GlcNAc
D-Glutamate
|
D-Glycerate
D-Glyceric acid
D-GroA
E
E 620
E620
E-620
Envision conditioner PDD 9020
Estrone, (+-)-isomer
Estrone, (8 alpha)-isomer
Estrone, (9 beta)-isomer
Estrovarin
ETA
Ethylolamine
FEMA NO. 3285
Follicular hormone
Folliculin
Glt
Glu
Glusate
Glut
Glutacid
Glutamate
Glutamate, potassium
GLUTAMIC ACID
Glutamic acid, (D)-isomer
Glutamicol
Glutamidex
Glutaminate
Glutaminic acid
Glutaminol
Glutaton
Glycerate
Glycine cholate
Glycinol
Glycocholate
Glycocholate sodium
Glycocholic acid, sodium salt
Glycoreductodehydrocholic acid
Glycylcholate
Glycylcholic acid
Hauck brand OF estrone
Hea
H-Glycinol
Hyrex brand OF estrone
INS NO.620
INS-620
Kestrone
L Glutamate
L Glutamic acid
L-(+)-Glutamate
L-(+)-Glutamic acid
L-a-Aminoglutarate
L-a-Aminoglutaric acid
L-alpha-Aminoglutarate
L-alpha-Aminoglutaric acid
L-Glu
L-Glu|L-glutamate|poly-L-glutamate
L-GLUTAMATE
L-Glutamate, aluminum
L-GLUTAMIC ACID
L-Glutaminate
L-Glutaminic acid
L-Glutaminsaeure
MEA
Monoaethanolamin
MONOETHANOLAMINE
N Acetyl D glucosamine
N-(Carboxymethyl)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-amide
N-(Carboxymethyl)-3α,7α,12α-trihydroxy-5β-cholan-24-amide
N-[(3a,5b,7a,12a)-3,7,12-Trihydroxy-24-oxocholan-24-yl]glycine
N-[(3alpha,5beta,7alpha,12alpha)-3,7,12-Trihydroxy-24-oxocholan-24-yl]glycine
N-[(3Α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]glycine
N-Acetylchitosamine
N-Acetyl-D-glucosamine
N-Choloylglycine
N-Choloyl-glycine
NSC-143503
Oestrone
Olamine
Potassium glutamate
R-Glycerate
R-Glyceric acid
Unigen
Vortech brand OF estrone
Wehgen
Α,β-hydroxypropionate
Α,β-hydroxypropionic acid
Î’-aminoethanol
Î’-aminoethyl alcohol
Î’-ethanolamine
Î’-hydroxyethylamine
|
|
31 |
|
Lysine |
Approved, Nutraceutical |
Phase 2 |
|
56-87-1 |
5962 |
Synonyms:
(+)-S-Lysine
(S)-2,6-Diaminohexanoate
(S)-2,6-Diamino-hexanoate
(S)-2,6-Diaminohexanoic acid
(S)-2,6-Diamino-hexanoic acid
(S)-a,e-Diaminocaproate
(S)-a,e-Diaminocaproic acid
(S)-a,epsilon-Diaminocaproate
(S)-a,epsilon-Diaminocaproic acid
(S)-alpha,epsilon-Diaminocaproate
(S)-alpha,epsilon-Diaminocaproic acid
(S)-Lysine
(S)-Α,epsilon-diaminocaproate
(S)-Α,epsilon-diaminocaproic acid
(S)-α,ε-diaminocaproic acid
2,6-Diaminohexanoate
2,6-Diaminohexanoic acid
6-Amino-aminutrin
6-Amino-L-norleucine
6-Ammonio-L-norleucine
Acetate, lysine
alpha-Lysine
|
a-Lysine
Aminutrin
Enisyl
H-Lys-OH
K
L Lysine
L-(+)-Lysine
L-2,6-Diainohexanoate
L-2,6-Diainohexanoic acid
L-2,6-Diaminocaproate
L-2,6-Diaminocaproic acid
L-Lys
L-Lysin
L-Lysine
Lys
Lysina
Lysine
Lysine acetate
Lysine acid
Lysine hydrochloride
Lysinum
|
|
32 |
|
PF-06700841 |
Investigational |
Phase 2 |
|
1883299-62-4 |
118878093 |
Synonyms:
BREPOCITINIB
compound 23 [PMID: 30113844]|PF-06700841|PF06700841
|
|
|
33 |
|
Vilobelimab |
Investigational |
Phase 2 |
|
2250440-41-4 |
|
Synonyms:
|
34 |
|
Antiprotozoal Agents |
|
Phase 1, Phase 2 |
|
|
|
35 |
|
Antiparasitic Agents |
|
Phase 1, Phase 2 |
|
|
|
36 |
|
Antimalarials |
|
Phase 1, Phase 2 |
|
|
|
37 |
|
Complement System Proteins |
|
Phase 2 |
|
|
|
38 |
|
Analgesics |
|
Phase 2 |
|
|
|
39 |
|
Phosphodiesterase Inhibitors |
|
Phase 2 |
|
|
|
40 |
|
Phosphodiesterase 4 Inhibitors |
|
Phase 2 |
|
|
|
41 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 2 |
|
|
|
42 |
|
Analgesics, Non-Narcotic |
|
Phase 2 |
|
|
|
43 |
|
Gastrointestinal Agents |
|
Phase 2 |
|
|
|
44 |
|
Interleukin 1 Receptor Antagonist Protein |
|
Phase 2 |
|
|
|
45 |
|
Protein Kinase Inhibitors |
|
Phase 2 |
|
|
|
46 |
|
interferons |
|
Phase 2 |
|
|
|
47 |
|
Janus Kinase Inhibitors |
|
Phase 2 |
|
|
|
48 |
|
Immunoglobulins |
|
Phase 2 |
|
|
|
49 |
|
Antibodies, Monoclonal |
|
Phase 2 |
|
|
|
50 |
|
Antibodies |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 155)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Cost-effectiveness of Adalimumab With Adjuvant Surgery Versus Adalimumab Monotherapy in the Treatment of Hidradenitis Suppurativa' |
Unknown status |
NCT03221621 |
Phase 4 |
Adalimumab Injection |
2 |
A Phase 4, Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction With Surgery in Subjects With Moderate to Severe Hidradenitis Suppurativa |
Completed |
NCT02808975 |
Phase 4 |
Placebo;Adalimumab |
3 |
A Randomized, Controlled Trial Comparing the Use of a Biodegradable Temporizing Matrix to Cadaver Skin in the Reconstruction of Hidradenitis Suppurativa Excisions |
Not yet recruiting |
NCT05477225 |
Phase 4 |
|
4 |
Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa |
Terminated |
NCT04582669 |
Phase 4 |
Intralesional Triamcinolone 10 mg/mL;Intralesional Triamcinolone 20 mg/mL;Intralesional Triamcinolone 40 mg/mL;Placebo |
5 |
Hidradenitis Suppurativa Patients' Experience of Treatment With Adalimumab |
Withdrawn |
NCT04132388 |
Phase 4 |
Adalimumab |
6 |
Spironolactone in the Treatment of Hidradenitis Suppurativa: A Prospective, Open-Label Proof-of-Concept and Dose-Ranging Study |
Withdrawn |
NCT04100083 |
Phase 4 |
Spironolactone 50 MG;Spironolactone 100mg;Spironolactone 200 mg |
7 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa |
Completed |
NCT04242498 |
Phase 3 |
Bimekizumab |
8 |
A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNRISE) |
Completed |
NCT03713632 |
Phase 3 |
Secukinumab;Placebo |
9 |
A Randomized, Double-blind, Multi-center Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNSHINE). |
Completed |
NCT03713619 |
Phase 3 |
secukinumab;Placebo |
10 |
A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension) |
Completed |
NCT01635764 |
Phase 3 |
|
11 |
A Phase 3 Multicenter, Open-label, Single Arm Study of the Safety and Efficacy of Adalimumab in Japanese Subjects With Moderate to Severe Hidradenitis Suppurativa |
Completed |
NCT02904902 |
Phase 3 |
adalimumab |
12 |
A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER I |
Completed |
NCT01468207 |
Phase 3 |
|
13 |
A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER II |
Completed |
NCT01468233 |
Phase 3 |
|
14 |
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa |
Recruiting |
NCT04179175 |
Phase 3 |
secukinumab |
15 |
A Single Center Clinical Trial to Evaluate the Effect of Sclerotherapy on Fistulas and Sinus Tracts in Adult Patients With Hidradenitis Suppurativa |
Recruiting |
NCT02805595 |
Phase 3 |
23.4% Hypertonic saline;Saline |
16 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa |
Active, not recruiting |
NCT04242446 |
Phase 3 |
Bimekizumab |
17 |
A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa |
Enrolling by invitation |
NCT04901195 |
Phase 3 |
Bimekizumab |
18 |
Rediscovery of Metformin for the Chronic Disabling Auto-inflammatory Disease Hidradenitis Suppurativa |
Not yet recruiting |
NCT04649502 |
Phase 3 |
|
19 |
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa |
Not yet recruiting |
NCT05620836 |
Phase 3 |
Povorcitinib;Placebo |
20 |
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa |
Not yet recruiting |
NCT05620823 |
Phase 3 |
Povorcitinib;Placebo |
21 |
To Determine The Efficacy Of A 1320nm Nd: YAG Nonablative Laser For Treatment of Hidradenitis Suppurativa |
Terminated |
NCT00367328 |
Phase 3 |
|
22 |
An Open-label Single Center Study to Evaluate the Efficacy of SILIQâ„¢ (Brodalumab) for the Treatment of Moderate Hidradenitis Suppurativa |
Unknown status |
NCT03910803 |
Phase 2 |
Brodalumab |
23 |
Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. The HiGUS-trial |
Unknown status |
NCT04061395 |
Phase 2 |
|
24 |
Pilot Study of Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa |
Completed |
NCT03275870 |
Phase 1, Phase 2 |
Hydroxychloroquine |
25 |
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa |
Completed |
NCT04019041 |
Phase 2 |
bermekimab;placebo |
26 |
Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis: A Randomised Double-blind Placebo Controlled Trial |
Completed |
NCT03049267 |
Phase 2 |
Apremilast;Placebo Oral Tablet |
27 |
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa |
Completed |
NCT03926169 |
Phase 2 |
Risankizumab;Placebo for risankizumab |
28 |
A Phase 2 Open-label Single Center Study to Evaluate the Efficacy of Apremilast for the Treatment of Moderate Hidradenitis Suppurativa |
Completed |
NCT02695212 |
Phase 2 |
Apremilast |
29 |
Open Label,Phase Two Study to Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa |
Completed |
NCT00827996 |
Phase 2 |
adalimumab |
30 |
An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa |
Completed |
NCT03001622 |
Phase 2 |
|
31 |
A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF-06650833, PF-06700841, AND PF-06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA |
Completed |
NCT04092452 |
Phase 2 |
PF-06650833;PF-06700841;PF-06826647;Placebo |
32 |
Proof of Concept Study on LTX-109 as Treatment for Hidradenitis Suppurativa |
Completed |
NCT04756336 |
Phase 1, Phase 2 |
LTX-109 gel, 3% w/w |
33 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa |
Completed |
NCT03852472 |
Phase 2 |
Avacopan |
34 |
Randomized, Double-blind, Placebo-controlled, Study of Spesolimab in Patients With Moderate to Severe Hidradenitis Suppurativa |
Completed |
NCT04762277 |
Phase 2 |
Spesolimab;Placebo |
35 |
A Double-blind, Randomised, Placebo-controlled Clinical Trial of the Efficacy of MABp1, a- First-in-class True Human Antibody Targeting Interleukin-1alpha, in Patients With Hidradenitis Suppurativa Not Eligible for antiTNF Therapy |
Completed |
NCT02643654 |
Phase 2 |
MABp1;Placebo |
36 |
Phase 2 Study to Assess the Safety and Efficacy of Infliximab for the Treatment of Hidradenitis Suppurativa |
Completed |
NCT00795574 |
Phase 2 |
infliximab;Placebo Comparator |
37 |
A Prospective Proof of Concept Study to Evaluate the Potential Efficacy of Ustekinumab in Patients With Moderate to Severe Hidradenitis Suppurativa (Acne Ectopica) |
Completed |
NCT01704534 |
Phase 2 |
Ustekinumab |
38 |
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients |
Completed |
NCT02421172 |
Phase 2 |
Placebo |
39 |
A Phase II Open Label Clinical Trial of Etanercept for the Treatment of Hidradenitis Suppurativa |
Completed |
NCT00107991 |
Phase 2 |
etanercept |
40 |
A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa |
Completed |
NCT03607487 |
Phase 2 |
INCB054707;Placebo |
41 |
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa |
Completed |
NCT04430855 |
Phase 2 |
Upadacitinib;Placebo Upadacitinib |
42 |
A Phase II, Open Label Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa |
Completed |
NCT03512275 |
Phase 2 |
Bermekimab Monoclonal Antibody 400 mg |
43 |
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects With Moderate to Severe Hidradenitis Suppurativa |
Completed |
NCT03628924 |
Phase 2 |
Guselkumab dose 1;Guselkumab dose 2;Guselkumab dose 3;Placebo |
44 |
A Phase 2 Study of the Safety and Efficacy of Etanercept for the Therapy of Hydradenitis Suppurativa |
Completed |
NCT00329823 |
Phase 2 |
Etanercept sc 50mg per week for 12 weeks |
45 |
A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa |
Completed |
NCT00918255 |
Phase 2 |
Placebo |
46 |
A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa |
Completed |
NCT03248531 |
Phase 2 |
Bimekizumab;Adalimumab |
47 |
A Phase 2, Open-Label, Single-Arm Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa |
Completed |
NCT03569371 |
Phase 2 |
INCB054707 |
48 |
A Double-blind, Randomized, Placebo-controlled Clinical Trial of the Safety and Efficacy of Anakinra in Patients With Hidradenitis Suppurativa |
Completed |
NCT01558375 |
Phase 2 |
Water for injection;Anakinra |
49 |
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa |
Completed |
NCT03487276 |
Phase 2 |
IFX-1;Placebo |
50 |
An Open Label Non-randomized Study Assessing the Efficacy and Tolerability of Fixed-dose Regimen Daily Subcutaneous Anakinra for the Treatment of Moderate to Severe Hidradenitis Suppurativa |
Completed |
NCT01516749 |
Phase 2 |
anakinra |
Cochrane evidence based reviews: hidradenitis
|